TY  - GEN
N2  - Public health, safety and access to reasonably priced medicine are common policy goals of pharmaceutical regulations. As both the context for innovation and competitive structure change, industry actors dynamically challenge the balance between the incentive for protection and the achievement of those policy goals.  Considering the arguments from the perspectives of innovation, competition law and patent law, this book explores the difficult question of balancing protection with access, highlighting the difficulties in harmonization and coordination. The contributors to this book, including academics, judges and practitioners from Europe, the US and Japan, explore to what extent patent strategies and life-cycle management practices take advantage of patent laws and health-care regulation and disrupt the necessary balance between incentives for innovation and access to affordable medicine and health care.  Addressing fundamental questions in the field of pharmaceutical innovation, this book will appeal to scholars and practitioners in intellectual property, competition law and life sciences regulation, as well as pharmaceutical companies and regulators.
AB  - Public health, safety and access to reasonably priced medicine are common policy goals of pharmaceutical regulations. As both the context for innovation and competitive structure change, industry actors dynamically challenge the balance between the incentive for protection and the achievement of those policy goals.  Considering the arguments from the perspectives of innovation, competition law and patent law, this book explores the difficult question of balancing protection with access, highlighting the difficulties in harmonization and coordination. The contributors to this book, including academics, judges and practitioners from Europe, the US and Japan, explore to what extent patent strategies and life-cycle management practices take advantage of patent laws and health-care regulation and disrupt the necessary balance between incentives for innovation and access to affordable medicine and health care.  Addressing fundamental questions in the field of pharmaceutical innovation, this book will appeal to scholars and practitioners in intellectual property, competition law and life sciences regulation, as well as pharmaceutical companies and regulators.
T1  - Pharmaceutical Innovation, Competition and Patent Law :A Trilateral Perspective.
AU  - Drexl, Josef.,
AU  - Lee, Nari.
AU  - Arnold, R.;
AU  - Bagley, M. A.;
AU  - Domeij, B.;
AU  - Drexl, J.;
AU  - Dreyfuss, R. C.;
AU  - Fackelmann, C. R.;
AU  - Imura, T.;
AU  - Iseki, R.;
AU  - Lee, N.;
AU  - Moufang, R.;
AU  - Ullrich, H.
CN  - K1519.D78
CN  - HD9665.5
LA  - eng
ID  - 27158
KW  - Drugs
KW  - Antitrust law
KW  - Pharmaceutical industry
KW  - Pharmaceutical industry
KW  - Product life cycle
KW  - Pharmaceutical industry.
KW  - Product life cycle.
KW  - Antitrust law.
KW  - Competition.
KW  - Patent laws and legislation.
KW  - Patents
KW  - Intellectual property
KW  - Pharmaceutical innovations
KW  - Patents
KW  - Compétitivité (Économie)
KW  - Médicaments
KW  - Brevets d'invention
KW  - Industrie pharmaceutique
SN  - 9780857932457
SN  - 9780857932464
TI  - Pharmaceutical Innovation, Competition and Patent Law :A Trilateral Perspective.
LK  - https://www.elgaronline.com/display/edcoll/9780857932457/9780857932457.xml
UR  - https://www.elgaronline.com/display/edcoll/9780857932457/9780857932457.xml
ER  -